Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Contrast Enhancement in Magnetic Resonance Imaging
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Trial Timeline
Jul 24, 2023 → Jun 1, 2024
NCT ID
NCT05915728About Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol is a phase 3 stage product being developed by Bayer for Contrast Enhancement in Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT05915728. Target conditions include Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05915728 | Phase 3 | Completed |
| NCT05915702 | Phase 3 | Completed |
Competing Products
11 competing products in Contrast Enhancement in Magnetic Resonance Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Gadoquatrane (BAY1747846) | Bayer | Phase 3 | 74 |
| GBCAs | Bayer | Pre-clinical | 20 |
| BAY1747846 | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoxetic acid disodium (Primovist, BAY86-4873) | Bayer | Approved | 82 |
| BAY1747846 + Matching placebo | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo | Bayer | Phase 1 | 30 |
| Gadobutrol (Gadavist/Gadovist, BAY86-4875) | Bayer | Pre-clinical | 20 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Magnevist + Dotarem + Gadovist | Guerbet | Pre-clinical | 15 |